Skip to content

Jiahuan Li

The Guangdong Provincial Key Laboratory of Cardiovascular Drug R and D Enterprises, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, Guangdong Province, China.

2 papers in the library · 3 citations · publishing 2024-2025

Papers

White matter integrity of default mode network after a 3-month aerobic dance program in patients with amnestic mild cognitive impairment: a secondary analysis of a randomized clinical trial.

Quantitative imaging in medicine and surgery March 3, 2025 Han Wu, Yi Zhu, Xi Yang et al. 2 citations

A 3-month aerobic dance program improved cognitive function and strengthened structural connections within the default mode network in older adults with amnestic mild cognitive impairment. Sixteen participants in the exercise group showed significant gains in global cognition, memory, and executive function compared to baseline, while the control group showed no change. The exercise group also had increased structural connections between the hippocampus and several temporal regions, as well as between the default mode network and the supplementary motor area. These connectivity changes correlated with better cognitive scores, suggesting that aerobic dance may enhance brain structure and memory in this population.

SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile.

Frontiers in pharmacology January 1, 2024 Ying Xiao, Xuefeng Hu, Wei Xing et al. 1 citation

A novel formulation combining deuterated dextromethorphan (SAL0114) with bupropion showed twice the metabolic stability of standard dextromethorphan in both laboratory and mouse tests, and bupropion further increased its exposure by 2.4 times. The combination demonstrated superior antidepressant and synergistic effects in mouse and rat models compared with the non-deuterated dextromethorphan-bupropion combination, while maintaining the same in vitro activity. Deuteration did not alter the compound's activity but improved its stability, potentially reducing neurologic side effects from metabolites and allowing lower bupropion doses. Clinical studies are needed to confirm these preclinical findings.